Resolution Bio Liquid Biopsy Outperforms Guardant Test in Lung Cancer Gene Fusion Detection

NEW YORK (GenomeWeb) – Researchers from the Dana-Farber Cancer Institute and Resolution Biosciences have identified more actionable gene fusion mutations with higher allele frequencies in lung cancer patients using Resolution Bioscience's ctDx-Lung liquid biopsy test than using Guardant Health's Guardant360 assay. GenomeWeb Premium gives you: Never miss another important industry story. You may already have institutional access! Already a GenomeWeb or 360Dx Premium member? *Before your trial expires, we’ll put together a custom quote with your long-term premium options.